Preliminary findings showed +80% of patients had increase in appetite and 60% +10% weight increase
ISRAEL & MARYLAND: Cannabics Pharmaceuticals, a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients.
Preliminary findings showed that all patients who were involved in the study for the first four and a half months reported an increase in appetite, as well as 83 percent of all those that completed the study. Results also demonstrated a weight increase of over 10 percent for 60 percent of the patients who completed the study. The remaining patients had a stable weight. 50 percent of the patients who completed the study reported pain reduction and sleep improvement.
“Our first clinical trial, led by Dr. Gil Bar-Sela, gave us valuable data on the capsules as a possible oral administration method for palliative care and for our future proprietary cannabinoid compounds,” said Dr. Eyal Ballan, co-founder and chief technology officer of Cannabics Pharmaceuticals. “As we continue to progress in the development of personalized cannabinoid treatments and collect data on compounds, ratios and dosages, we will use the information to incorporate into the design of our next clinical study on cancer patients.”